Woman loses 115 lbs of phentermine, Topamax and Lexapro with Robert Skversky, MD

Robert Skversky, MD. Woman loses 115 lbs with phentermine (Adipex-P), Lexapro (escitalopram oxalate) and Topamax (topiramate). Off-label use of drugs. Phen-Pro. Robert Skversky, MD is a weight loss doctor in Newport Beach, California. Robert Skversky, MD Weight No More Medical Associates — Newport Beach Office 320 Superior Avenue, Suite 210 Newport Beach, CA 92663 (949) 645-2930 phone (949) 645-1059 fax www.WeightNoMore.com info@weightnomore.com View Map of the Newport Beach Office Location: maps.google.com Weight No More Medical Associates—Temecula Office 28441 Rancho California Road, Suite 104 Temecula, CA 92590 (951) 699-0848 phone (951) 699-0509 fax info@weightnomore.com View Map of the Temecula Office Location: maps.google.com “Before” and “After” photos of weight loss patients: www.weightnomore.com Testimonials www.weightnomore.com Patient Information www.weightnomore.com Locations and Hours www.weightnomore.com Patient Education www.weightnomore.com The Program www.weightnomore.com About Robert Skversky, MD www.weightnomore.com Originally from Philadelphia, Dr. Skversky received his medical degree from Hahnemann University (formerly Hahnemann Medical College) in 1970. He completed his family practice residency at Hoag Memorial Hospital in Newport Beach, CA, in 1973 and became a diplomate of the American Board of Family Practice the same year. Dr. Skversky is a staff physician at Hoag Memorial Hospital, a member of the American Medical Association, Orange County
Video Rating: 4 / 5

Bookmark/share via AddInto

Phentermine plus Topamax causes woman to lose 55 lbs, man 73 lbs

Hi, this is Larry Hobbs @ FatNew.com. This video clip talks about the diet drug Qnexa, which is Phentermine plus Topamax (topiramate), Contrave which is naltrexone plus bupropion, and lorcaserin.
Video Rating: 5 / 5

LX4211 Enhances Effects of DPP-4 Inhibition in Patients with Type 2 Diabetes
Shares of Arena Pharmaceuticals (NASDAQ:ARNA) +0.57% shot up 11% early Tuesday on news the FDA has accepted its resubmitted application for the diet-drug lorcaserin. The agency is expected to decide whether to approve the product by June 27.
Read more on BioMedReports (subscription)

Bookmark/share via AddInto